Evidence map›Paper›PMID 38084093›Full record

ArticleCancer discovery2023

Re-"Formate" T-cell Antitumor Responses.

Mei-Chun Lin, Sofie Hedlund Moller, Ping-Chih Ho

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. MTHFD2: a promising metabolic checkpoint for diseases.Journal of translational medicine · 2026
    Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Mei-Chun LinDepartment of Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1133-6741
Sofie Hedlund MollerDepartment of Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2268-4277
Ping-Chih HoDepartment of Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3078-3774
Ludwig Cancer Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryRowe and colleagues discover that one-carbon (1C) metabolism rewiring occurs upon T-cell activation to support proliferation and cytolytic activity in CD8+ T cells and that supplementation of 1C donor formate rescues the dysfunctional T cells and their responsiveness to anti-PD-1 in selective tumor-infiltrated T-cell subsets. This finding represents an attractive strategy to overcome a metabolic vulnerability in the tumor microenvironment and improve the efficacy of immune checkpoint blockade. See related article by Rowe et al., p. 2566 (8).

Indexed as

NeoplasmsProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesFormatesHumansLymphocyte ActivationTumor MicroenvironmentFormatesProgrammed Cell Death 1 Receptor

Identifiers

PMID38084093
OpenAlexW4389618747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.